ORGANIZED BY:

Department of Medical
and Surgical Sciences (DIMEC)
Alma Mater Studiorum
University of Bologna, Italy

Division of Renal Diseases and Hypertension
University of Colorado
Anschutz Medical Campus
Aurora-CO, USA

INTERNATIONAL
SYMPOSIUM ON:

URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE

After more than a century of active research, uric acid has gained the stage as of one of the most reliable candidates for the huge amount of residual cardio-metabolic risk.

The involvement of uric acid in the pathophysiology of hypertension, diabetes and metabolic syndrome, particularly at younger ages, supports the importance of the research in this area.

The interaction between genetics, biochemistry, epidemiology and lifestyle is the engine that has boosted the worldwide interest for uric acid and cardio-metabolic disease.

Now is time to move from academy to clinical practice since we urgently need a reliable tool to identify which patients deserve something more than theory and hypothesis.

The 4th edition of the Bologna meeting will be focused on the patient with the goal to discuss several burning topics:

- Are all the patients with elevated serum uric acid levels the same?
- What is the threshold level for "cardio-metabolic" hyperuricemia?
- How to identify the patients at risk of cardio-metabolic disease?
- What about in children and adolescents?
- What are the differences with cardiovascular complicated gout?
- What are the preventive/therapeutic strategies?
- What is the role of ULT?
- What advantages/harm of the use of non-ULT drugs affecting uric acid?
- What is the current position of Guidelines?

INTERNATIONAL SYMPOSIUM ON:

URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE

WITH THE ENDORSEMENT OF:

PRESIDENT OF THE MEETING:
Claudio Borghi
Department of Medical and Surgical Sciences (DIMEC)
Department of Internal Medicine
Alma Mater Studiorum University of Bologna
St. Orsola-Malpighi University Hospital (Bologna, Italy)

CO-ORGANIZER:
Richard J. Johnson
Division of Renal Diseases and Hypertension, University of Colorado
Anschutz Medical Campus (Aurora-CO, USA)

SCIENTIFIC SECRETARIAT:
Arrigo F.G. Cicero
Alma Mater Studiorum University of Bologna (Bologna, Italy)
Agostino Virdis
University of Pisa (Pisa, Italy)

ORGANIZING SECRETARIAT AND PROVIDER FOR ITALIAN CME ACCREDITATION:
I&C s.r.l.
Via Andrea Costa, 202/6, 40134 Bologna (Italy)
Tel.: +39 051 6144004 - Fax: +39 051 6142772
E-mail: stefania.parolari@iec-srl.it - roberta.loggini@iec-srl.it
Website: www.iec-srl.it

WITH AN UNRESTRICTED GRANT BY:
Fondazione Internazionale Menarini
Centro Direzionale Milanofiori
20089 Rozzano (Milan, Italy) Edificio L – Strada 6
Phone: +39 02 55308110 - Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
Website: www.fondazione-menarini.it

Tuesday, November 13th, 2018 – Morning
Salone del Podestà - Palazzo Re Enzo

09.00 a.m.	Introduction to the meeting objectives **C. Borghi** (Bologna, IT)

Session I – The cardio-metabolic burden in patients with gout

Chairpersons:	**E. Agabiti Rosei** (Brescia, IT) **T. Gibson** (London, UK)
09.20 a.m.	**F. M. Galassi** (Adelaide, AU) Uric acid and gout: tales from the Ancient World
09.40 a.m.	**L. Punzi** (Padua, IT) The cardio-metabolic involvement in gout. The position of guidelines
10.00 a.m.	**D. Rothenbacher** (Ulm, DE) How can we quantify the cardio-metabolic risk in patients with gout? An epidemiological perspective
10.20 a.m.	**M. Andrés** (Alicante, ES) The management of cardio-metabolic risk in patients with gout
10.40 a.m.	**M. M. Givertz** (Boston-MA,US) Treating gout in patients with cardiovascular disease
11.00 a.m.	General discussion
11.30 a.m.	*Coffee break*
12.00 p.m.	Main Lecture *Introduction:* **E. Ambrosioni** (Bologna, IT), **M. H. Alderman** (New York-NY, US) **R. J. Johnson** (Aurora-CO, US) From uric acid to cardio-metabolic disease: can we identify the patients at risk?
01.00 p.m.	*Lunch*

Tuesday, November 13th, 2018 – Afternoon
Salone del Podestà - Palazzo Re Enzo

Session II – Update on the clinical evidence: uric acid and cardiovascular disease

Chairpersons:	**P. Palatini** (Padua, IT) **J. Redon** (Valencia, ES)
02.00 p.m.	**A. Virdis** (Pisa, IT) Uric acid and blood pressure
02.20 p.m.	**S. G. Wannamethee** (London, UK) Uric acid, left ventricular function and heart failure
02.40 p.m.	**G. Ambrosio** (Perugia, IT) Uric acid and coronary artery disease
03.00 p.m.	**K. Tsioufis** (Athens, GR) Uric acid and atrial fibrillation
03.20 p.m.	General discussion
03.40 p.m.	*Coffee break*

Session III – Update on the clinical evidence: uric acid, metabolic and renal disease

Chairpersons:	**M. Burnier** (Lausanne, CH) **C. Borghi** (Bologna, IT)
04.10 p.m.	**D. H. Kang** (Seoul, KR) Uric acid and new-onset metabolic syndrome
04.30 p.m.	**M. Kuwabara** (Tokyo, JP) The interaction between uric acid and lipid profile
04.50 p.m.	**R. Pontremoli** (Genoa, IT) Uric acid and renal dysfunction: what is the egg?
05.10 p.m.	**R. Cifkova** (Prague, CZ) Uric acid, pregnancy and cardio-renal disease
05.30 p.m.	General discussion
06.00 p.m.	Conclusion and end of the sessions

Wednesday, November 14th, 2018 – Morning
Salone del Podestà - Palazzo Re Enzo

08.30 a.m.	Introduction to the meeting objectives **C. Borghi** (Bologna, IT)

Session IV – Quantification of cardio-metabolic risk in patients with hyperuricemia

Chairpersons:	**G. Mancia** (Milan, IT) **A. J. Manolis** (Athens, GR)
09.00 a.m.	**C. Ferri** (L'Aquila, IT) Is drug-induced hyperuricemia a cardio-metabolic risk factor?
09.20 a.m.	**T. R. Merriman** (Dunedin, NZ) Is genetic approach the right solution?
09.40 a.m.	**J. Dawson** (Glasgow, UK) Is genetic profile useful for clinical practice?
10.00 a.m.	**M. Burnier** (Lausanne, CH) Is the measure of xantino-oxidase a reliable tool?
10.20 a.m.	**L. Scheepers,** (Gothenburg, SE) Is it reasonable to consider a functional index?
10.40 a.m.	General discussion
11.00 a.m.	*Coffee break*

Session V – Prevention of cardio-metabolic risk in patients with hyperuricemia

Chairpersons:	**M. L. Muiesan** (Brescia, IT) **K. Narkiewicz** (Gdansk, PL)
11.30 a.m.	**E. Lurbe** (Valencia, ES) Age-dependent prevention of hyperuricemia: the earlier is the better?
11.50 a.m.	**D. I. Feig** (Birmingham-AL, US) The role of fructose consumption and dietary approach
12.10 a.m.	**G. Grassi** (Milan, IT) The management of additional risk factors in patients with hyperuricemia
12.30 p.m.	**G. Desideri** (L'Aquila, IT) Is the determination of serum uric acid enough?
12.50 p.m.	General discussion
01.00 p.m.	*Lunch*

Wednesday, November 14th, 2018 – Afternoon
Salone del Podestà - Palazzo Re Enzo

Session VI – Hyperuricemia and cardio-metabolic risk: who is to treat?

Chairpersons:	**S. Taddei** (Pisa, IT) **A. J. Manolis** (Athens, GR)
02.00 p.m.	**P.M. Nilsson** (Malmo, SE) SGLT-2 inhibitors and control of uric acid: mechanism and potential advantages
02.20 p.m.	**J. George** (Dundee, UK) Urate lowering drugs and prevention of cardiometabolic disease: the evidence
02.40 p.m.	**S. Masi** (Pisa, IT) Recent evidence in cardiorenal protection with Urate Lowering Treatment
03.00 p.m.	**A. Stack** (Limerick, IE) Is there any "J-shaped" curve for serum uric acid?
03.20 p.m	**C. Borghi** (Bologna, IT) Hyperuricemia and cardiometabolic disease: the role of renal impairment
03.40 p.m.	**A. D. Struthers** (Dundee, UK) The treatment of asimptomatic hyperuricemia: who, when and why
04.00 p.m.	**L. G. Sanchez-Lozada** (Mexico City, MX) The non-pharmacologic approach to hyperuricemia. Solutions beyond diet
04.20 p.m.	**J. T. Kielstein** (Braunschweig, DE) How to investigate the cardiovascular and renal effects of urate-lowering drugs?
04.40 p.m.	General discussion
05.10 p.m.	Closing Remarks and end of the Symposium



General Information

Meeting venue

The venue for the Meeting is **Salone del Podestà, Palazzo Re Enzo** - Piazza del Nettuno, 1 - Bologna

Secretariat desk during the meeting

The secretariat desk is open at the following times:
Tuesday, November 13th, from 08.00 a.m. to 06.00 p.m.
Wednesday, November 14th, from 08.00 a.m. to 05.30 p.m.

Official language

The official language of the Meeting is English.

Registration

The Meeting is free to attend. The registration link is available on the website www.iec-srl.it until November 8th. Onsite registrations can be accepted.

Technical facilities speakers

Facilities are available for computer presentations and overhead projections.
A slide center with PC (Powerpoint for Windows) is available for check and preview of presentations.
It is essential that speakers take their presentations to the slide center at least one hour before the session starts.
The slide center is open at the following times:
Tuesday, November 13th, from 08.00 a.m. to 06.00 p.m.
Wednesday, November 14th, from 08.00 a.m. to 05.30 p.m.

Lunches and coffee breaks

Lunches and coffee breaks are served in the Congress area.

Abstracts book

Participants can get the abstract book at the Symposium.

Certificate of attendance

The certificate of attendance is available, on request, at the end of the Meeting at the secretariat desk.

CME Credits

EACCME and EBAC Credits have been obtained for physicians for the following disciplines: Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene.

Italian CME credits

Provider Italian CME Credits: I&C s.r.l. 5387 (event number 240472)
Number of credits: 4,2
I&C s.r.l. is responsible for the content, the quality and the ethical honesty of the CME activity.
The meeting is accredited for the following professions: Nurse, Pharmacist, Biologist, Physician (specialties: Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene). The physicians belonging to other specialties will not get the credits.
The attendance to the meeting is partially on sponsor companies invitation.
METHODOLOGY: Residential
COURSE OBJECTIVES: Clinical, Diagnostic, Therapy, Treatment Path
In order to obtain CME credits, it is mandatory for participants to attend 90% of the course (both days) and to complete CME procedures online: learners' feedback form and educational needs form. Instructions are provided on site.

General Information

EACCME Credits

The "URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE", Bologna, Italy, 13/11/2018-14/11/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 14 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.
In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:
13.11.2018 - 7,00
14.11.2018 - 7,00
The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

EBAC Credits

The event "URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE" (Ref. 00004467), is accredited by the European Board for Accreditation in Cardiology for 13 CME credit hour(s) (Day #1: 7 CME credit(s) - Day #2: 6 CME credit(s)).

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Faculty

Enrico Agabiti-Rosei
Department of Clinical and Experimental Sciences
University of Brescia
Spedali Civili di Brescia
Brescia (Italy)

Michael H. Alderman
Distinguished University Professor Emeritus
Departments of Medicine and Population Health
Albert Einstein College of Medicine
Bronx, New York-NY (USA)

Giuseppe Ambrosio
Department of Cardiology
University of Perugia
S. Maria della Misericordia Hospital
Perugia (Italy)

Ettore Ambrosioni
Internal Medicine
University of Bologna (Former Professor)
Bologna (Italy)

Mariano Andrés
Department of Rheumatology
General University Hospital of Alicante
Miguel Hernández University
Alicante (Spain)

Claudio Borghi
Department of Medical and Surgical Sciences (DIMEC)
Department of Internal Medicine
Alma Mater Studiorum University of Bologna
St. Orsola-Malpighi University Hospital
Bologna (Italy)

Michel Burnier
Nephrology and Hypertension
Department of Medicine
Vaud University Hospital Center
Lausanne (Switzerland)

Renata Cifkova
Center of Cardiovascular Prevention
First Faculty of Medicine
Charles University, Thomayer Hospital
Prague (Czech Republic)

Jesse Dawson
Institute of Cardiovascular and Medical Sciences
University of Glasgow
Queen Elizabeth University Hospital
Glasgow (United Kingdom)

Giovambattista Desideri
Division of Geriatric Medicine
University of L'Aquila
SS Filippo and Nicola Hospital
Avezzano-L'Aquila (Italy)

Daniel I. Feig
Division of Nephrology, Pediatrics
University of Alabama
Birmingham-AL (USA)

Claudio Ferri
Division of Internal Medicine and Nephrology
School of Internal Medicine
University of L'Aquila
San Salvatore Hospital
Coppito - L'Aquila (Italy)

Francesco M. Galassi
College of Humanities, Arts and Social Sciences
Flinders University
Adelaide - SA (Australia)

Jacob George
Cardiovascular Medicine & Therapeutics
TASC Research and Development Office
Tayside Medical Sciences Centre
University of Dundee, Ninewells Hospital
Dundee (United Kingdom)

Terence Gibson
Department Acute Medicine
Guy's and St Thomas'
NHS Foundation Trust
London (United Kingdom)

Michael M. Givertz
Cardiovascular Division
Brigham and Women's Hospital
Harvard Medical School
Boston-MA (USA)

Guido Grassi
Internal Medicine, School of Medicine and Surgery
University of Milano-Bicocca
St. Gerardo Hospital, Monza
Milan (Italy)

Richard J. Johnson
Division of Renal Diseases and Hypertension
University of Colorado
Anschutz Medical Campus
Aurora-CO (USA)

Duk-Hee Kang
Department of Internal Medicine
Division of Nephrology
Ewha Women's University
College of Medicine
Seoul (Korea)

Jan T. Kielstein
Nephrology and Rheumatology Department
Academic Teaching Hospital Braunschweig
Braunschweig (Germany)

Masanari Kuwabara
Department of Cardiology
Toranomon Hospital
Tokyo (Japan)

Empar Lurbe
Pediatrics Department
University of Valencia,
Clinical Hospital of Valencia
Valencia (Spain)

Giuseppe Mancia
University of Milano-Bicocca
Milan (Italy)

Athanasios J. Manolis
Department of Cardiology
"Asklepeion" General Hospital
Athens (Greece)

Stefano Masi
Department of Clinical and Experimental Medicine
University of Pisa
Pisa (Italy)

Tony R. Merriman
Biochemistry Department
School of Medical Sciences
University of Otago
Dunedin (New Zealand)

Maria Lorenza Muiesan
Internal Medicine, School of Emergency Medicine
University of Brescia
Department of Medicine – Spedali Civili of Brescia
Brescia (Italy)

Krzysztof Narkiewicz
Department of Hypertension and Diabetology
Medical University of Gdansk
Gdansk (Poland)

Peter M. Nilsson
Lund University
Department Clinical Sciences
Skane University Hospital
Malmo (Sweden)

Paolo Palatini
Department of Medicine
University of Padua
Padua (Italy)

Roberto Pontremoli
Department of Internal Medicine
and Medical Specialties
University of Genoa
Genoa (Italy)

Leonardo Punzi
Rheumatology Unit
Department of Medicine Medical School
University of Padua
Padua (Italy)

Josep Redon
Department of Internal Medicine
University of Valencia, Clinical Hospital of Valencia
Valencia (Spain)

Dietrich Rotenbacher
Institute of Epidemiology and Medical Biometry
Ulm University
Ulm (Germany)

L. Gabriela Sanchez-Lozada
Department of Nephrology
National Institute of Cardiology Ignacio Chávez
Mexico City (Mexico)

Lieke Scheepers
Biometrics, Early Clinical Development
IMED Biotech Unit, AstraZeneca
Gothenburg (Sweden)

Austin Stack
Department of Nephrology
University Hospital Limerick &
Graduate Entry Medical School University of Limerick
Limerick (Ireland)

Allan D. Struthers
Cardiovascular Medicine
Medical Research Institute
Division of Molecular and Clinical Medicine
University of Dundee
Dundee (United Kingdom)

Stefano Taddei
Department of Internal Medicine
University of Pisa
Pisa (Italy)

Konstantinos Tsioufis
First Cardiology Clinic, Medical School
National and Kapodistrian University of Athens
Hippokration Hospital
Athens (Greece)

Agostino Virdis
Department of Clinical and Experimental Medicine
University of Pisa
Pisa (Italy)

Sasiwarang Goya Wannamethee
Primary Care and Population Health
UCL Medical School
London (United Kingdom)

NOTES

NOTES

With an
unrestricted grant by

FONDAZIONE
INTERNAZIONALE
MENARINI